Eli Lilly's stock surged after it reported a 48% year-over-year revenue increase, driven by strong demand for its diabetes treatment Mounjaro and obesity drug Zepbound. The company now holds a 60.9% share of the U.S. obesity and diabetes drug market, and it raised its full-year revenue guidance, reinforcing investor confidence.
In contrast, Novo Nordisk, despite also beating estimates and raising its outlook, faced a negative reaction from investors due to concerns over its pipeline and future growth prospects. Analysts noted that while Novo's diabetes drug Ozempic performed well, its new Wegovy pill fell slightly short of expectations, raising doubts about its potential as a growth driver.
Additionally, mixed results from a key experimental obesity drug, CagriSema, and a failed cardiovascular drug trial have further fueled skepticism about Novo's ability to diversify its portfolio. As a result, Lilly is seen as the momentum leader in the market, while Novo is in a phase where it must prove its turnaround strategy to investors